A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses

Monoclonal antibodies (MAbs) that interfere with checkpoint molecules are being investigated for the treatment of infectious diseases and cancer, with the aim of enhancing the function of an impaired immune system. Avelumab (MSB0010718C) is a fully human IgG1 MAb targeting programmed death-ligand 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Grenga, Italia, Donahue, Renee N, Lepone, Lauren M, Richards, Jacob, Schlom, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910121/
https://www.ncbi.nlm.nih.gov/pubmed/27350882
http://dx.doi.org/10.1038/cti.2016.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910121/
https://www.ncbi.nlm.nih.gov/pubmed/27350882
http://dx.doi.org/10.1038/cti.2016.27

Ejemplares similares